The Food and Drug Administration (FDA) in the USA has granted Orphan Drug Designation to ISA Pharmaceuticals BV, an immunotherapy company, for its lead product ISA101b, intended for the treatment of Human Papilloma Virus type 16 (HPV16)-positive cervical cancer, it was reported on Wednesday.
The therapeutic is a clinical-stage immunotherapy targeting HPV16-induced diseases and induces specific immune responses to the oncogenic E6 and E7 proteins of HPV16 and is based on ISA Pharmaceuticals BV's proprietary Synthetic Long Peptide technology. It is designed to mount a highly specific, broad and durable, T-cell mediated attack by the immune system on tumours that are positive for human papilloma virus type 16
ISA101 has indicated that it is an effective monotherapy in patients with early stage, HPV16 positive, premalignant neoplasias.
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma